< Back to previous page
Patent
Dual targeting of tafi and pai-1
Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).
Patent Publication Number: EP3102610
Year filing: 2020
Year approval: 2020
Year publication: 2020
Status: Assigned
URI: link to Espacenet
Technology domains: Biotechnology
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven